Dr Emily Sammons
Contact information
Emily Sammons
BSc, MBChB, MSc
Clinical Research Fellow
Dr Emily Sammons is a Clinical Research Fellow and DPhil student at the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), with particular research interests in diabetic eye disease and age-related macular degeneration.
Alongside this, she works on two large randomised controlled trials: ASCEND and REVEAL.
ASCEND is studying whether aspirin and omega-3 fish oil supplementation protects against cardiovascular disease in people with diabetes.
REVEAL is assessing the safety and benefits of taking a new lipid-modifying drug called anacetrapib, by those with pre-existing atherosclerotic vascular disease.
Emily has background experience of working in General Medicine and a MSc in Public Health.
Recent publications
-
Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial.
Journal article
Scotland G. et al, (2025), Diabet Med
-
Experience of linking to the NHS diabetic eye screening programme records in the ASCEND-eye randomized trial and recommendations for improvement.
Journal article
Sammons E. et al, (2025), Contemp Clin Trials Commun, 45
-
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Journal article
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
-
Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes.
Journal article
Sammons E. et al, (2025), BMJ Open, 15
-
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Journal article
EMPA-KIDNEY Collaborative Group None. et al, (2025), N Engl J Med, 392, 777 - 787